The Penicillin Paradox: Overcoming Allergy Labels and Barriers to Desensitization in the ICU

academic.oup.com June 30, 2026

While roughly 10% of patients carry a penicillin allergy label, formal testing reveals that over 90% of these labels are completely inaccurate. In ICUs, where severe infections demand urgent, optimal treatment, this mislabeling frequently forces clinicians to bypass first-line beta-lactam antibiotics in favor of broader-spectrum alternatives, driving up healthcare costs and spiking the risk of multi-drug resistant infections.

To understand how critical care teams navigate this dilemma, this study deployed an anonymous online survey to U.K. intensive care clinicians between 2020 and 2021, evaluating their clinical practices, knowledge gaps, and specific barriers to implementing penicillin desensitization protocols.

The survey gathered insights from 118 clinicians across 33 U.K. hospitals, the majority of whom were consultants. While respondents correctly estimated that about 13% of their patients claim a penicillin allergy, a staggering 60% believed that the vast majority of these patients could actually tolerate the drug safely.

In fact, 85% of doctors admitted to “sometimes” or “often” overriding an allergy label when a patient’s medical history suggested a low risk. Despite this awareness, actual experience with penicillin desensitization was virtually non-existent, with 90% of respondents having never performed the procedure in an ICU setting.

The hesitation to utilize desensitization stems from systemic hurdles rather than a lack of interest. Clinicians cited a lack of local allergy or immunology expertise (51%), unfamiliarity with the procedure (39%), safety anxieties in critically ill patients (26%), and the perceived workload for nursing staff (24%) as major deterrents, compounding the fact that only 31% of hospitals had on-site allergy services.

The study concludes that building structured, collaborative pathways between ICU and allergy specialists—alongside clear protocols and targeted education—could dismantle these misconceptions, safely expanding first-line antibiotic options and sharpening antimicrobial stewardship where it matters most.